vTv Therapeutics Inc.
vTv Therapeutics Inc. (Nasdaq: TTVT) is a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases. The company's website is www.vtvtherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What vTv Therapeutics Inc. does
In the company’s own words
vTv Therapeutics Inc. (Nasdaq: TTVT) is a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases. The company's website is www.vtvtherapeutics.com.
The company's lead product candidate is cadisegliatin (TTP399), a novel small-molecule liver-selective glucokinase activator currently in Phase 3 clinical development as a potential oral adjunctive therapy to insulin for type 1 diabetes. Cadisegliatin received FDA Breakthrough Therapy designation in 2021 based on positive Phase 2 results demonstrating a 40 percent reduction in severe hypoglycemia and statistically significant improvements in hemoglobin A1c compared to placebo. The Phase 3 CATT1 trial is designed to evaluate cadisegliatin's effect on reducing hypoglycemia frequency in 150 patients with type 1 diabetes, with enrollment expected to complete in the third quarter of 2026. In December 2025, vTv and partner G42 Investments initiated a Phase 2 trial in the Middle East evaluating cadisegliatin in 300 insulin-dependent patients with type 2 diabetes.
Beyond its lead program, vTv maintains a pipeline of earlier-stage candidates including TTP273, an oral small-molecule GLP-1 receptor agonist that demonstrated statistically significant reductions in hemoglobin A1c in a Phase 2 trial; TTP-RA, a RAGE antagonist in preclinical development for type 1 diabetes prevention; HPP593, a PPAR-delta agonist; and Nrf2/Bach1 modulators targeting oxidative stress and inflammation across multiple disease areas.
The company has established strategic partnerships to advance its pipeline. vTv licensed HPP737, an oral PDE4 inhibitor, to Newsoara BioPharma globally in January 2026, receiving a $20 million upfront payment with potential milestone payments up to $115 million and royalties on future sales. vTv also licensed azeliragon, a RAGE antagonist, to Cantex Pharmaceuticals for worldwide development and commercialization. Additionally, vTv holds a license from Novo Nordisk covering glucokinase activator intellectual property and programs.
In September 2025, vTv completed a private placement raising approximately $80 million in gross proceeds, with investors receiving additional warrants potentially bringing total proceeds to $200 million. The company does not operate manufacturing facilities and relies on third-party manufacturers for clinical supplies and research materials.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- HIGH POINT, NC
- Fiscal year end
- December
- CIK
- 1641489
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns vTv Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · vTv Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do vTv Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of vTv Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in vTv Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”